Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33-3-20-16-40-00
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees148
Next Earnings DateN/A
OptionableNot Optionable
GENFIT S A/ADR (NASDAQ:GNFT) Frequently Asked Questions
What is GENFIT S A/ADR's stock symbol?
GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT."
What price target have analysts set for GNFT?
6 brokerages have issued twelve-month price objectives for GENFIT S A/ADR's stock. Their forecasts range from $25.47 to $72.00. On average, they expect GENFIT S A/ADR's stock price to reach $52.6175 in the next year. This suggests a possible upside of 215.3% from the stock's current price. View Analyst Price Targets for GENFIT S A/ADR.
What is the consensus analysts' recommendation for GENFIT S A/ADR?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GENFIT S A/ADR.
Has GENFIT S A/ADR been receiving favorable news coverage?
Press coverage about GNFT stock has trended positive this week, according to InfoTrie. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GENFIT S A/ADR earned a news impact score of 2.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for GENFIT S A/ADR.
Who are some of GENFIT S A/ADR's key competitors?
Some companies that are related to GENFIT S A/ADR include Acceleron Pharma (XLRN), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Regenxbio (RGNX), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), Alector (ALEC) and Twist Bioscience (TWST).
What other stocks do shareholders of GENFIT S A/ADR own?
Who are GENFIT S A/ADR's key executives?
GENFIT S A/ADR's management team includes the folowing people:
- Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)
- Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)
- Dr. Dean W. Hum, Chief Operating Officer (Age 57)
- Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)
- Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49)
When did GENFIT S A/ADR IPO?
(GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.
When does GENFIT S A/ADR's lock-up period expire?
GENFIT S A/ADR's lock-up period expires on Monday, September 23rd. GENFIT S A/ADR had issued 6,150,000 shares in its IPO on March 27th. The total size of the offering was $124,968,000 based on an initial share price of $20.32. After the end of GENFIT S A/ADR's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Who are GENFIT S A/ADR's major shareholders?
GENFIT S A/ADR's stock is owned by many different of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (2.98%), Cormorant Asset Management LP (0.85%), CVI Holdings LLC (0.37%), Victory Capital Management Inc. (0.17%), Bank of America Corp DE (0.12%) and United Services Automobile Association (0.11%).
Which institutional investors are selling GENFIT S A/ADR stock?
GNFT stock was sold by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Syquant Capital Sas, Man Group plc, Orbimed Advisors LLC, Victory Capital Management Inc., Jane Street Group LLC, Cormorant Asset Management LP and United Services Automobile Association.
Which institutional investors are buying GENFIT S A/ADR stock?
GNFT stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Balyasny Asset Management LLC, Boussard & Gavaudan Investment Management LLP and Morgan Stanley.
How do I buy shares of GENFIT S A/ADR?
Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GENFIT S A/ADR's stock price today?
One share of GNFT stock can currently be purchased for approximately $16.69.
How big of a company is GENFIT S A/ADR?
What is GENFIT S A/ADR's official website?
How can I contact GENFIT S A/ADR?
GENFIT S A/ADR's mailing address is PARC EURASANTE 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected]
MarketBeat Community Rating for GENFIT S A/ADR (NASDAQ GNFT)
MarketBeat's community ratings are surveys of what our community members think about GENFIT S A/ADR and other stocks. Vote "Outperform" if you believe GNFT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNFT will underperform the S&P 500 over the long term. You may vote once every thirty days.
